Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia

American Journal of Hematology
Selmin AtaerginAhmet Ozet

Abstract

A 38-year-old female with chronic myeloid leukemia underwent an allogeneic bone marrow transplantation from her full-matched brother. Eleven months later, she readmitted with an acute leukemia that was shown to be of donor origin. The patient never achieved a remission even after chemotherapies with cytarabine and mitoxantrone, donor lymphocyte infusion, and second allogeneic peripheral blood stem cell transplantation. Donor cell leukemia (DCL) is sometimes misdiagnosed as relapse by clinicians and the real incidence may be higher than expected. Cytogenetic and molecular techniques may be helpful to clarify the issue of the leukemia. The current case is another case of DCL reported in the literature after an allogeneic transplant for a kind of leukemia.

References

Jul 1, 1985·British Journal of Haematology·J L SmithA J Provisor

❮ Previous
Next ❯

Citations

Feb 19, 2013·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Navid TabrizDirk Weyhe
Aug 21, 2009·International Journal of Hematology·Natsue IgarashiKeiichi Nemoto
Feb 28, 2007·Leukemia & Lymphoma·Guillermo J Ruiz-ArgüellesJavier Garcés-Eisele
Oct 19, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel H Wiseman
Dec 2, 2010·The Korean Journal of Hematology·Seong Hyun JeongJoon Seong Park
Mar 10, 2021·Bone Marrow Transplantation·Lacey WilliamsCatherine Lai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.